Spots Global Cancer Trial Database for entospletinib
Every month we try and update this database with for entospletinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Entospletinib (ENTO [GS-9973]) Combined With Vincristine (VCR) in Adult Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL) | NCT02568683 | Non-Hodgkin Lym... | Entospletinib Vincristine | 18 Years - | Gilead Sciences | |
| Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies | NCT02457598 | B-cell Malignan... | Tirabrutinib Idelalisib Entospletinib Obinutuzumab | 18 Years - | Gilead Sciences | |
| Safety and Efficacy of Entospletinib With Vincristine and Dexamethasone in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) | NCT02404220 | Acute Lymphobla... | Entospletinib Vincristine Dexamethasone CNS Prophylaxis | 18 Years - | Gilead Sciences | |
| Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML) | NCT02343939 | Acute Myeloid L... | Entospletinib Daunorubicin Cytarabine Decitabine Azacitidine | 18 Years - | Gilead Sciences | |
| Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma | NCT03010358 | Anemia B-Cell Prolymph... Grade 1 Follicu... Grade 2 Follicu... Grade 3a Follic... Hairy Cell Leuk... Lymphoplasmacyt... Mantle Cell Lym... Marginal Zone L... Recurrent Chron... Recurrent Small... Refractory Chro... Refractory Smal... Richter Syndrom... | Entospletinib Laboratory Biom... Obinutuzumab Pharmacological... | 18 Years - | OHSU Knight Cancer Institute | |
| Entospletinib Plus Intensive Induction/Consolidation Chemotherapy in Newly Diagnosed NPM1-mutated AML | NCT05020665 | Nucleophosmin 1... | Entospletinib Placebo Cytarabine Anthracycline | 18 Years - 74 Years | Kronos Bio | |
| Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies | NCT01796470 | Chronic Lymphoc... Mantle Cell Lym... Diffuse Large B... Indolent Non-Ho... | Entospletinib Idelalisib | 18 Years - | Gilead Sciences | |
| Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies | NCT01796470 | Chronic Lymphoc... Mantle Cell Lym... Diffuse Large B... Indolent Non-Ho... | Entospletinib Idelalisib | 18 Years - | Gilead Sciences | |
| Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML) | NCT02343939 | Acute Myeloid L... | Entospletinib Daunorubicin Cytarabine Decitabine Azacitidine | 18 Years - | Gilead Sciences | |
| Entospletinib (ENTO) as Monotherapy and in Combination With Chemotherapy in Japanese Adults | NCT03135028 | Hematologic Mal... Acute Myeloid L... | Entospletinib Daunorubicin Cytarabine | 18 Years - | Gilead Sciences | |
| Pharmacokinetics of Entospletinib in Adults With Normal and Impaired Liver Function | NCT02521376 | Oncology | Entospletinib | 18 Years - | Gilead Sciences | |
| Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML) | NCT02343939 | Acute Myeloid L... | Entospletinib Daunorubicin Cytarabine Decitabine Azacitidine | 18 Years - | Gilead Sciences | |
| Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma | NCT03010358 | Anemia B-Cell Prolymph... Grade 1 Follicu... Grade 2 Follicu... Grade 3a Follic... Hairy Cell Leuk... Lymphoplasmacyt... Mantle Cell Lym... Marginal Zone L... Recurrent Chron... Recurrent Small... Refractory Chro... Refractory Smal... Richter Syndrom... | Entospletinib Laboratory Biom... Obinutuzumab Pharmacological... | 18 Years - | OHSU Knight Cancer Institute | |
| Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies | NCT02457598 | B-cell Malignan... | Tirabrutinib Idelalisib Entospletinib Obinutuzumab | 18 Years - | Gilead Sciences |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
